HIGH

Fujirebio Diagnostics Recalled pTau 217 Plasma Cartridges

Fujirebio Diagnostics recalled 1,569 units of Lumipulse G pTau 217 Plasma Immunoreaction Cartridges on December 11, 2025. The recall affects users due to potential inaccurate test results associated with Alzheimer's disease classifications. Customers in 13 states should stop using the product immediately.

Quick Facts at a Glance

Recall Date
December 11, 2025
Hazard Level
HIGH
Brand
Fujirebio Diagnostics
Category
Health & Personal Care
Sold At
Multiple Retailers
Geographic Scope
1 states
At-Risk Groups
GENERAL

Hazard Information

Customers may experience inaccurate test results by observing a higher frequency of classification in the indeterminate and positive zone and/or low specificity when compared back to FDA-cleared CSF ratio/PET imaging, due to falsely elevated positive ratio or falsely elevated indeterminate ratio results causing an incorrect classification of a patient as having amyloid pathology associated with Alzheimer s disease (positive result) and/or requiring more clinical testing of that patient (indeterminate result).

What You Should Do

Patients and healthcare providers should stop using this device immediately. Follow the recall instructions provided by the manufacturer. Contact Fujirebio Diagnostics, Inc. or your healthcare provider for instructions. Notification method: Letter

Get instant alerts for Health & Personal Care recalls

Be the first to know. Free instant alerts to your inbox.

No spamUnsubscribe anytime

Product Details

The recall involves Lumipulse G pTau 217 Plasma Immunoreaction Cartridges, Model/Catalog Number: 81550. A total of 1,569 units were distributed across 13 states in the U.S.

The Hazard

Customers may receive inaccurate test results, with an increased chance of false classifications regarding amyloid pathology linked to Alzheimer's disease. This could lead to unnecessary clinical tests and misdiagnosis.

Reported Incidents

No specific incidents or injuries have been reported. The hazard is classified as a high risk due to potential misdiagnosis.

What to Do

Stop using the Lumipulse G pTau 217 Plasma Immunoreaction Cartridges immediately. Follow recall instructions from Fujirebio Diagnostics and consult your healthcare provider.

Contact Information

For further information, contact Fujirebio Diagnostics, Inc. or visit their website. More details are available at the FDA recall page.

Key Facts

  • Recall date: December 11, 2025
  • Active recall status
  • Affected states: Arizona, California, Florida, Indiana, Kansas, Kentucky, Maryland, Massachusetts,
  • Minnesota, New Jersey, Pennsylvania, Texas, Washington

Get Alerts for Health & Personal Care Recalls

Get instant alerts for recalls that affect you. Free forever.

Safety Assessment

Risk LevelHIGH
Severity Score
8/ 10
Affected Groups
GENERAL
Injury Types
OTHER

Product Details

Model Numbers
Model/Catalog Number: 81550
UDI-DI: 05414470815500
Lot Numbers: D4C6028U
D4C6029U
D4C6051U
+1 more
Affected States
ALL
Report Date
February 11, 2026
Recall Status
ACTIVE

Related Recalls

HIGH

Fresenius Kabi Vancomycin Injection Recalled Over Sterility Concerns

Fresenius Kabi Compounding recalled its vancomycin HCl injection on February 5, 2026, due to a lack of assurance of sterility. This Class II recall affects all lots distributed nationwide. Healthcare providers and consumers must stop using the product immediately.

Fresenius Kabi Compounding
Lack of
Read more
HIGH

Fresenius Kabi Compounding Issues Recall of Vancomycin Injection

Fresenius Kabi Compounding recalled 1,578 bags of vancomycin HCl injection on February 5, 2026. The company cited a lack of assurance of sterility as the reason for the recall. Healthcare providers and consumers should stop using the product immediately.

Fresenius Kabi Compounding
Lack of
Read more
HIGH

Pro Numb Tattoo Numbing Spray Recalled Due to cGMP Violations

Pro Numb Tattoo Numbing Spray was recalled on February 2, 2026 due to cGMP deviations. The product, containing 4% lidocaine, is distributed by Pro Numb Tattoo Numbing Spray LLC. Consumers should stop using it immediately and contact the company for further guidance.

PRO NUMB SENSITIVE SKIN
cGMP deviations
Read more